Lexicon Pharmaceuticals

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Lexicon Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#347 of 15,742 sponsors by registered trial count).

56 total trials 1 currently recruiting 51 completed early-phase tilt top decile by trial count

Lexicon Pharmaceuticals: 56 sponsored US clinical trials, 1 recruiting.

Lexicon Pharmaceuticals sponsors 56 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 51 completed. 17 of these trials are in Phase 3-4 (later-stage) and 39 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Type 2 Diabetes Mellitus, with 3 trials.

Top-decile sponsor footprint

Lexicon Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#347 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

C 72/100

51 of 55 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (92.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

56 total, page 2 of 2

COMPLETED Phase 1

Study of Two Oral Formulations of LX4211 in Patients With Type 2 Diabetes Mellitus

NCT01188863
COMPLETED Phase 2

Study of LX4211 in Subjects With Type 2 Diabetes Mellitus

NCT00962065
COMPLETED Phase 2

Study of LX3305 in Subjects With Active Rheumatoid Arthritis on Stable Methotrexate

NCT00903383
COMPLETED Phase 2

Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy

NCT00853047
COMPLETED Phase 1

Study of LX3305 and Methotrexate in Subjects With Stable Rheumatoid Arthritis

NCT00847886
COMPLETED Phase 2

Study of LX1031 in Subjects With Non-Constipating Irritable Bowel Syndrome

NCT00813098
← Previous Page 2 of 2

Phase Distribution

PhaseTrial count
Phase 1 25
Phase 2 14
Phase 3 17

Therapeutic Areas

Type 2 Diabetes Mellitus 3
Carcinoid Syndrome 1
Non-obstructive Hypertrophic Cardiomyopathy 1
Obstructive Cardiomyopathy, Hypertrophic 1
Drug Interactions 1
Diabetic Peripheral Neuropathy 1
Diabetes 1
Type 1 Diabetes Mellitus 1
Ulcerative Colitis 1
Irritable Bowel Syndrome 1

What is open in the Lexicon Pharmaceuticals pipeline

1 recruiting of 56 indexed (2% open); 51 completed (91%).

Phase mix: 17 late (III/IV) vs 39 early (I/II) (early-phase heavy).

Top condition: Type 2 Diabetes Mellitus (3 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Lexicon Pharmaceuticals: open-pipeline peers nationwide

Peers matched on 56 registered trials and 2% open enrollment, not the therapeutic-area sidebar.

Lexicon Pharmaceuticals sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0100200300 0%5%10%15%20% Total trials Recruiting share Lexicon PharmaceuticalsEdwards LifesciencesSt. Luke's-Roosevelt Hospital CenterSupernus PharmaceuticalsUSDA Grand Forks Human Nutrition Research CenterAlcon ResearchLundquist Institute for Biomedical Innovation at Harbor-UCLA Medical CenterEisaiMedtronic Cardiac Rhythm and Heart Failure
Lexicon Pharmaceuticals sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Lexicon Pharmaceuticals sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 56 trials (± recruiting share)

Sponsors near 2% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Lexicon Pharmaceuticals page

56 registered trials is a research-attention snapshot, not an endorsement of Lexicon Pharmaceuticals or any single study.

  • 1 of Lexicon Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Type 2 Diabetes Mellitus is the condition Lexicon Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Type 2 Diabetes Mellitus trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Lexicon Pharmaceuticals pipeline card: 56 registered trials from official public datasets.Report a data error.